# US 2017/0281674 A1 · Process For Generating Nanometer Sized Particles That Increase Oxygen Levels In Mammalian Tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281674 A1
- Document ID: US20170281674A1
- Status: Published application
- Kind: A1
- Application number: 15/188,586
- Filed: 2016-06-21
- Published: 2017-10-05
- Earliest claimed: 2016-03-30
- Assignees: Baylor University
- Applicants: Baylor University
- Inventors: Christie Sayes; Erica D. BRUCE; John W. WOODMANSEE, JR.
- Web page: https://patentgrep.com/patent/US20170281674A1

## CPC

- A61K 33/08: Oxides; Hydroxides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A61K 9/1682: {Processes}
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C01F 7/02: Aluminium oxide; Aluminium hydroxide; Aluminates
- C01F 7/023: Grinding, deagglomeration or disintegration
- A61K 9/5115: {Inorganic compounds}
- C01P 2004/61: Micrometer sized, i.e. from 1-100 micrometer
- C01P 2004/62: Submicrometer sized, i.e. from 0.1-1 micrometer
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C01F: COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts of peroxyacids C01B15/00; sulfides or polysulfides of magnesium, calcium, strontium, or barium C01B17/42; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds other than ammonia or cyanogen containing nitrogen and non-metals and optionally metals C01B21/082; amides or imides of silicon C01B21/087}; metal {imides or} amides C01B21/092, {C01B21/0923}; nitrites C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; compounds having molecular sieve properties but not having base-exchange properties C01B37/00; compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites, C01B39/00; cyanides C01C3/08; salts of cyanic acid C01C3/14; salts of cyanamide C01C3/16; thiocyanates C01C3/20; {double sulfates of magnesium with sodium or potassium C01D5/12; with other alkali metals C01D15/00, C01D17/00})
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A composition and process to produce poly-oxygenated metal hydroxide particles on the nanometer size scale. The relevant particle size includes all size populations ranging from 1 nanometer (nm) to 3000 nanometers (nm) or 3 micrometer (μm) in particle diameter. Filtering may be used to create homogeneous particle sizes. Exemplary delivery applications include inhalation, ingestion, anally, vaginally, dermal penetration or permeation, intramuscular injection, and intravenous injection to treat numerous conditions and diseases of mammals, including humans and animals.

## Claims

### Claim 1

A process for generating reduced sized particles of poly-oxygenated metal hydroxide, comprising the step of:
obtaining predetermined quantity of poly-oxygenated metal hydroxide material;
determining process variables as a function of the predetermined quantity; and
processing the predetermined quantity of poly-oxygenated metal hydroxide material using the determined process variables to create a processed quantity poly-oxygenated metal hydroxide material having particle sizes of less than or equal to 3 μm in diameter.

### Claim 2 (depends on 1)

The process as specified in claim 1 wherein the processed quantity of oxygenated metal hydroxide material is homogenous.

### Claim 3 (depends on 1)

The process as specified in claim 1, further comprising the step of:
analyzing the processed quantity of poly-oxygenated metal hydroxide material to confirm the particle sizes are less than or equal to 3 μm in diameter.

### Claim 4 (depends on 1)

The process as specified in claim 1 further comprising the step of using a planetary motion machine to perform the processing step.

### Claim 5 (depends on 1)

The process as specified in claim 1 wherein the process variables are determined based on a milling scale.

### Claim 6 (depends on 1)

The process as specified in claim 1 wherein the poly-oxygenated metal hydroxide material comprises a poly-oxygenated aluminum hydroxide.

### Claim 7 (depends on 2)

The process as specified in claim 2 wherein the processing step creates a homogenous quantity of poly-oxygenated metal hydroxide material having particle sizes of less than or equal to 250 nm diameter.

### Claim 8

A composition, comprising:
a quantity poly-oxygenated aluminum hydroxide having particle sizes of less than or equal to 3 μm in diameter, wherein the poly-oxygenated metal hydroxide comprises a clathrate containing free oxygen gas (O2) molecules.

### Claim 9 (depends on 8)

The composition as specified in claim 8, wherein the quantity of poly-oxygenated aluminum hydroxide is homogeneous.

### Claim 10 (depends on 8)

The composition as specified in claim 8, wherein the homogenous quantity of poly-oxygenated aluminum hydroxide has particle sizes of less than or equal to 250 nm in diameter.

### Claim 11

canceled

### Claim 12

canceled

### Claim 13 (depends on 8)

The composition as specified in claim 8 wherein poly-oxygenated aluminum hydroxide is therapeutically effective in treating a condition of a mammal.

### Claim 14 (depends on 8)

The composition as specified in claim 8 wherein the poly-oxygenated aluminum hydroxide is configured to be intravenously delivered to a mammal.

### Claim 15 (depends on 8)

The composition as specified in claim 8 wherein the poly-oxygenated aluminum hydroxide is configured to not create an immune response of the mammal.

### Claim 16 (depends on 8)

The composition as specified claim 8 wherein the poly-oxygenated aluminum hydroxide is configured to deposit deep into a lung and perfuse the oxygen gas out to lining of the lung.

### Claim 17 (depends on 8)

The composition as specified in claim 8 wherein the oxygen gas is configured to penetrate through epidermis and dermis layers of skin and reside in a subcutaneous layer of the skin.

### Claim 18 (depends on 8)

The composition as specified in claim 8 wherein the oxygen gas is configured to absorb through lining of an esophagus and a stomach.

### Claim 19 (depends on 8)

The composition as specified in claim 8 wherein the poly-oxygenated hydroxide is configured to traverse a blood brain barrier (BBB) of a mammal.

### Claim 20 (depends on 8)

The composition as specified in claim 8 wherein the poly-oxygenated aluminum hydroxide is configured to stay in a capillary, vein, or artery linings of a mammal circulatory system and not passively diffuse past a lining into surrounding tissue.